Which Is Promising As Therapeutic Targets In Patients With Biliary Tract Cancer? EGFR Or HER2?

A research team from Germany analyzed the pathogenetic role and potential clinical usefulness of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancer (BTC). They found that routine testing and therapeutic targeting of HER2 does not seem to be useful in patients with BTC, while targeting EGFR may be promising.

Read the whole article on Science Daily

More from Science Daily